Pharmacokinetic studies with the antifolate C2-desamino-C2-methyl-N10-propargyl-2'-trifluoromethyl-5,8-dideazafolic acid (CB3988) in mice and rats using in vivo '9F-NMR spectroscopy
1990

Pharmacokinetic Studies of Antifolate Drug CB3988 Using NMR Spectroscopy

Sample size: 6 publication Evidence: moderate

Author Information

Author(s): D.R. Newell, R.J. Maxwell, G.M.F. Bisset, D.I. Jodrell, J.R. Griffiths

Primary Institution: Institute of Cancer Research

Hypothesis

The study aims to evaluate the pharmacokinetics of the antifolate drug CB3988 using non-invasive '9F-NMR spectroscopy.

Conclusion

CB3988 is rapidly cleared from the body through biliary and urinary excretion, and '9F-NMR spectroscopy is a useful method for studying its pharmacokinetics.

Supporting Evidence

  • CB3988 was detected in both the gall bladder and urinary bladder after administration.
  • NMR signal from the upper abdomen peaked at 10-40 minutes post-administration.
  • Comparison with HPLC showed similar results for drug concentrations in bile and urine.
  • CB3988 was cleared rapidly from the body, contrasting with the nephrotoxic drug CB3717.

Takeaway

Scientists used a special technique to see how a new cancer drug moves through mice and rats, and they found it leaves the body quickly.

Methodology

The study used '9F-NMR spectroscopy to track the drug's movement in mice and rats after intravenous administration.

Limitations

The sensitivity of NMR is limited, which may restrict its application to drugs that can be administered in larger doses.

Participant Demographics

Male C57BL x DBA2 Fl hybrid mice and female Wistar rats were used.

Statistical Information

P-Value

0.004

Statistical Significance

p=0.004

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication